Baseline characteristics of Ph-like ALL, categorized as CRLF2+ and non-CRLF2
| . | Ph-like ALL, N = 56 . | P . | |
|---|---|---|---|
| CRLF2+ . | Non-CRLF2 . | ||
| N | 37 | 19 | |
| Age, y, median (range) | 35 (18-71) | 26 (15-62) | .12 |
| Sex, n (%) | |||
| Female | 10 (27) | 9 (47) | .13 |
| Male | 27 (73) | 10 (53) | |
| Ethnicity, n (%) | |||
| White | 8 (22) | 5 (26) | |
| Hispanic | 29 (78) | 9 (48) | .008 |
| African American | — | 2 (10) | |
| Asian | — | 3 (16) | |
| Cytogenetics, n = 49, n (%) | |||
| Diploid | 15 (45) | 4 (25) | .49 |
| Hyperdiploid | 6 (18) | 4 (25) | |
| Hypodiploid | 3 (9) | 1 (6) | |
| Miscellaneous | 9 (28) | 7 (44) | |
| Presenting features | |||
| WBC, ×109/L, median (range) | 27.7 (1-603) | 5.3 (1-81) | .001 |
| Platelet count, ×109/L, median (range) | 36 (1-169) | 41 (8-238) | .55 |
| Hemoglobin, g/dL, median (range) | 9.4 (6.5-13.7) | 9.2 (5.7-15.1) | .19 |
| Bone marrow blast %, median (range) | 92 (62-98) | 87 (17-99) | .17 |
| CNS involvement at Dx, n (%) | 5 (14) | 3 (16) | .82 |
| IKZF1 deleted, n = 41, n (%) | 21/25 (84%) | 7/16 (44%) | .014 |
| Treatment received, n (%) | |||
| Hyper-CVAD based | 29 (78) | 8 (42) | .007 |
| Augmented BFM | 8 (22) | 11 (58) | |
| . | Ph-like ALL, N = 56 . | P . | |
|---|---|---|---|
| CRLF2+ . | Non-CRLF2 . | ||
| N | 37 | 19 | |
| Age, y, median (range) | 35 (18-71) | 26 (15-62) | .12 |
| Sex, n (%) | |||
| Female | 10 (27) | 9 (47) | .13 |
| Male | 27 (73) | 10 (53) | |
| Ethnicity, n (%) | |||
| White | 8 (22) | 5 (26) | |
| Hispanic | 29 (78) | 9 (48) | .008 |
| African American | — | 2 (10) | |
| Asian | — | 3 (16) | |
| Cytogenetics, n = 49, n (%) | |||
| Diploid | 15 (45) | 4 (25) | .49 |
| Hyperdiploid | 6 (18) | 4 (25) | |
| Hypodiploid | 3 (9) | 1 (6) | |
| Miscellaneous | 9 (28) | 7 (44) | |
| Presenting features | |||
| WBC, ×109/L, median (range) | 27.7 (1-603) | 5.3 (1-81) | .001 |
| Platelet count, ×109/L, median (range) | 36 (1-169) | 41 (8-238) | .55 |
| Hemoglobin, g/dL, median (range) | 9.4 (6.5-13.7) | 9.2 (5.7-15.1) | .19 |
| Bone marrow blast %, median (range) | 92 (62-98) | 87 (17-99) | .17 |
| CNS involvement at Dx, n (%) | 5 (14) | 3 (16) | .82 |
| IKZF1 deleted, n = 41, n (%) | 21/25 (84%) | 7/16 (44%) | .014 |
| Treatment received, n (%) | |||
| Hyper-CVAD based | 29 (78) | 8 (42) | .007 |
| Augmented BFM | 8 (22) | 11 (58) | |